Contact
searchSearch
HMP Global

News

News
Dorzolamide and Timolol Ophthalmic Solution Recalled Due to Defective Containers
08/06/2026
Rebecca Amrick
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate...
08/06/2026
Pharmacy Learning Network
News
Azelaic Acid Gel Recalled Due to CGMP Deviations
08/06/2026
Rebecca Amrick
A voluntary Class II recall has been issued for azelaic acid gel due to Current Good Manufacturing Practice (CGMP) deviations, resulting from the product’s abnormal texture.
A voluntary Class II recall has been issued for azelaic acid gel due to Current Good Manufacturing Practice (CGMP) deviations, resulting from the product’s abnormal texture.
A voluntary Class II recall has...
08/06/2026
Pharmacy Learning Network
News
Mycophenolate Mofetil Recalled Due to the Presence of Precipitate
08/06/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for mycophenolate mofetil due to the presence of precipitate, affecting 5688 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for mycophenolate mofetil due to the presence of precipitate, affecting 5688 vials.
The US Food and Drug...
08/06/2026
Pharmacy Learning Network
PharmLaw
Arkansas Suspends Enforcement of Specialty Drug Distribution Law Following Constitutional Challenge
08/05/2026
Hannah Musick
The Arkansas State Board of Pharmacy has suspended enforcement of a law restricting manufacturers' use of limited drug distribution networks after a federal court found the statute likely violates the dormant Commerce Clause, setting up a...
The Arkansas State Board of Pharmacy has suspended enforcement of a law restricting manufacturers' use of limited drug distribution networks after a federal court found the statute likely violates the dormant Commerce Clause, setting up a...
The Arkansas State Board of...
08/05/2026
Pharmacy Learning Network
News
Lidocaine Hydrochloride Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has...
07/30/2026
Pharmacy Learning Network
News
Glycopyrrolate Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are...
07/30/2026
Pharmacy Learning Network
News
Amlodipine and Olmesartan Medoxomil Tablets Recalled Due to Failed Dissolution Specifications
07/30/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug...
07/30/2026
Pharmacy Learning Network
PharmLaw
EyePoint Pharmaceuticals Agrees to $4.6 Million False Claims Act Settlement
07/29/2026
Grace Taylor, MS, MA
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has...
07/29/2026
Pharmacy Learning Network
News
CareOne Carbamide Peroxide Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Cleviprex Recalled Due to Lack of Sterility Assurance
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use